Selected article for: "clinical evidence and disease progression"

Author: Cordon-Cardo, Carlos; Pujadas, Elisabet; Wajnberg, Ania; Sebra, Robert; Patel, Gopi; Firpo-Betancourt, Adolfo; Fowkes, Mary; Sordillo, Emilia; Paniz-Mondolfi, Alberto; Gregory, Jill; Krammer, Florian; Simon, Viviana; Isola, Luis; Soon-Shiong, Patrick; Aberg, Judith A.; Fuster, Valentin; Reich, David L.
Title: COVID-19: Staging of a New Disease
  • Cord-id: hwrahmr5
  • Document date: 2020_10_10
  • ID: hwrahmr5
    Snippet: Coronavirus disease 2019 (COVID-19), like cancer, is a complex disease with clinical phases of progression. Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized as a multi-organ and heterogeneous illness. Disease staging is a method for measuring the progression and severity of an illness using objective clinical and molecular criteria. Integral to cancer staging is “metastasis,” defined as the spread of a disease-producing agent, including neoplastic cells
    Document: Coronavirus disease 2019 (COVID-19), like cancer, is a complex disease with clinical phases of progression. Initially conceptualized as a respiratory disease, COVID-19 is increasingly recognized as a multi-organ and heterogeneous illness. Disease staging is a method for measuring the progression and severity of an illness using objective clinical and molecular criteria. Integral to cancer staging is “metastasis,” defined as the spread of a disease-producing agent, including neoplastic cells and pathogens such as certain viruses, from the primary site to distinct anatomic locations. Staging provides valuable frameworks and benchmarks for clinical decision-making in patient management, improved prognostication, and evidence-based treatment selection.

    Search related documents:
    Co phrase search for related documents
    • acid amplification test and additional risk: 1
    • active viral infection and liver kidney: 1
    • acute period and liver kidney: 1
    • additional risk and liver kidney: 1, 2, 3